Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics.

TitlePerspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics.
Publication TypeJournal Article
Year of Publication2018
AuthorsDing, L, Bailey, MH, Porta-Pardo, E, Thorsson, V, Colaprico, A, Bertrand, D, Gibbs, DL, Weerasinghe, A, Huang, K-L, Tokheim, C, Cortés-Ciriano, I, Jayasinghe, R, Chen, F, Yu, L, Sun, S, Olsen, C, Kim, J, Taylor, AM, Cherniack, AD, Akbani, R, Suphavilai, C, Nagarajan, N, Stuart, JM, Mills, GB, Wyczalkowski, MA, Vincent, BG, Hutter, CM, Zenklusen, JClaude, Hoadley, KA, Wendl, MC, Shmulevich, L, Lazar, AJ, Wheeler, DA, Getz, G
Corporate AuthorsCancer Genome Atlas Research Network
JournalCell
Volume173
Issue2
Pagination305-320.e10
Date Published2018 Apr 05
ISSN1097-4172
KeywordsCarcinogenesis, Databases, Genetic, DNA Repair, Genes, Neoplasm, Genomics, Humans, Metabolic Networks and Pathways, Microsatellite Instability, Mutation, Neoplasms, Transcriptome, Tumor Microenvironment
Abstract

The Cancer Genome Atlas (TCGA) has catalyzed systematic characterization of diverse genomic alterations underlying human cancers. At this historic junction marking the completion of genomic characterization of over 11,000 tumors from 33 cancer types, we present our current understanding of the molecular processes governing oncogenesis. We illustrate our insights into cancer through synthesis of the findings of the TCGA PanCancer Atlas project on three facets of oncogenesis: (1) somatic driver mutations, germline pathogenic variants, and their interactions in the tumor; (2) the influence of the tumor genome and epigenome on transcriptome and proteome; and (3) the relationship between tumor and the microenvironment, including implications for drugs targeting driver events and immunotherapies. These results will anchor future characterization of rare and common tumor types, primary and relapsed tumors, and cancers across ancestry groups and will guide the deployment of clinical genomic sequencing.

DOI10.1016/j.cell.2018.03.033
Alternate JournalCell
PubMed ID29625049
PubMed Central IDPMC5916814
Grant ListP30 ES010126 / ES / NIEHS NIH HHS / United States
P30 CA016672 / CA / NCI NIH HHS / United States
U24 CA143882 / CA / NCI NIH HHS / United States
U54 HG003067 / HG / NHGRI NIH HHS / United States
U24 CA143835 / CA / NCI NIH HHS / United States
U24 CA143866 / CA / NCI NIH HHS / United States
P30 CA016086 / CA / NCI NIH HHS / United States
U24 CA210950 / CA / NCI NIH HHS / United States
U24 CA143845 / CA / NCI NIH HHS / United States
U24 CA143799 / CA / NCI NIH HHS / United States
U54 HG003273 / HG / NHGRI NIH HHS / United States
U24 CA144025 / CA / NCI NIH HHS / United States
U24 CA143840 / CA / NCI NIH HHS / United States
U24 CA143843 / CA / NCI NIH HHS / United States
U24 CA210974 / CA / NCI NIH HHS / United States
U24 CA143858 / CA / NCI NIH HHS / United States
U24 CA143848 / CA / NCI NIH HHS / United States
U24 CA210957 / CA / NCI NIH HHS / United States
U54 HG003079 / HG / NHGRI NIH HHS / United States
U24 CA210949 / CA / NCI NIH HHS / United States
U24 CA210988 / CA / NCI NIH HHS / United States
U24 CA143883 / CA / NCI NIH HHS / United States
U24 CA211006 / CA / NCI NIH HHS / United States
R01 CA163722 / CA / NCI NIH HHS / United States
R25 DA027995 / DA / NIDA NIH HHS / United States
U24 CA143867 / CA / NCI NIH HHS / United States
R50 CA221675 / CA / NCI NIH HHS / United States
U24 CA210990 / CA / NCI NIH HHS / United States

Similar Publications